How is medication prescribing ceased?: A systematic review

Medical Care

Volumn 49, Issue 1, 2011, Pages 24-36

  Ostini, Remo ^a   Jackson, Claire ^a   Hegney, Desley ^a,b   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

ceasing prescribing; costs of prescribing; prescribing interventions; quality improvement

Indexed keywords

BENZODIAZEPINE; PRESCRIPTION DRUG;

COST EFFECTIVENESS ANALYSIS; DATA BASE; DATA EXTRACTION; EVIDENCE BASED MEDICINE; FEEDBACK SYSTEM; HUMAN; INTERPERSONAL COMMUNICATION; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCREENING; SYSTEMATIC REVIEW;

CLINICAL TRIALS AS TOPIC; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; REMINDER SYSTEMS;

EID: 78650709889     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181ef9a7e     Document Type: Review

References (60)

1. Avorn JL. Powerful Medicines: The Benefits, Risks and Costs of Prescription Drugs. New York, NY: Knopf; 2004.
2. Australian Commission on Safety and Quality in Health. National medication safety and quality scoping study. Sydney, Australia: ACSQH 2009.
3. National Audit Office. Repeat Prescribing by General Medical Practitioners in England. London, United Kingdom: National Audit Office; 1993.
4. National Audit Office. GP prescribing behaviour 2006: report into the findings of a survey of general practitioners in England. London, United Kingdom: National Audit Office; 2006.
5. Runciman WB, Roughead EE, Semple SJ, et al. Adverse drug events and medication errors in Australia. Int J Qual Health Care. 2003;15:i49-i59.
6. National Audit Office. Prescribing Costs in Primary Care. Technical Supplement. London, United Kingdom: National Audit Office; 2007.
7. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-2724.
8. Agashivala N, Wu WK. Effects of potentially inappropriate psychoactive medications on falls in US nursing home residents: analysis of the 2004 National Nursing Home Survey database. Drugs Aging. 2009;26: 853-860. DOI: 10.2165/1131680000000000000000.
9. Bongue B, Naudin F, Laroche ML, et al. Trends of the potentially inappropriate medication consumption over 10 years in older adults in the East of France. Pharmacoepidemiol Drug Saf. 2009;18:1125-1133. DOI: 10.1002/pds. 1762.
10. Stefanacci RG, Cavallaro E, Beers MH, et al. Developing explicit positive beers criteria for preferred central nervous system medications in older adults. Consult Pharm. 2009;24:601-610.
11. Steinman MA, Rosenthal GE, Landefeld CS, et al. Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing. Arch Intern Med. 2009;169:1326-1332. DOI: 10.1001/archinternmed. 2009.206.
12. Hajjar ER, Hanlon JT, Sloane RJ, et al. Unnecessary drug use in frail older people at hospital discharge. J Am Geriatr Soc. 2005;53:1518-1523. JGS53523 DOI: 10.1111/j.1532-5415.2005.53523.x. (Pubitemid 41602441)
13. Bennett JW, Glasziou P, Del Mar C, et al. A computerised prescribing decision support system to improve patient adherence with prescribing. A randomised controlled trial. AustFam Physician. 2003;32:667-671.
14. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-1224.
15. Dodds F, Rebair Brown A, Parsons S. A systematic review of randomized controlled trials that attempt to identify interventions that improve patient compliance with prescribed antipsychotic medication. Clin Effect Nurs. 2000;4:47-53.
16. Lindenmeyer A, Hearnshaw H, Vermeire E, et al. Interventions to improve adherence to medication in people with type 2 diabetes melli-tus: a review of the literature on the role of pharmacists. J Clin Pharm Ther. 2006;31:409-419.
17. Ostini R, Hegney D, Jackson C, et al. Systematic review of interventions to improve prescribing. Ann Pharmacother. 2009;43:502-513. DOI: 10.1345/aph. 1L488.
18. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [Updated September 2006]. Chichester, United Kingdom John Wiley & Sons, Ltd. 2006.
19. The Joanna Briggs Institute. Comprehensive Systematic Review Training Program Manual and Workbook. Adelaide, South Australia: Joanna Briggs Institute 2007.
20. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet. 1999;354:1896-900.
21. Oxman AA, Guyatt GH. Validation of an index of the quality of review articles. J Clin Epidemiol. 1991;44:1271-1278.
22. Bailey TC, Ritchie DJ, McMullin ST, et al. Randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at 2 tertiary care teaching institutions. Pharmacotherapy. 1997;17:277-281.
23. Bashir K, King M, Ashworth M. Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract. 1994;44:408-412.
24. Gleason PP, Solberg CL, Brelje TV, et al. Assessment of a retrospective drug utilization review alert letter program. J Clin Outcomes Manag. 2004;11:150-154.
25. Gorgels WJ, Oude Voshaar RC, Mol AJ, et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend. 2005;78:49-56.
26. Kroenke K, Pinholt EM. Reducing polypharmacy in the elderly. A controlled trial of physcian feedback. J Am Geriatr Soc. 1990;38:31-36.
27. Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther. 2004;19:917-922. doi: 10.1111/j. 1365-2036.2004.01928.x.
28. Midmer D, Kahan M, Marlow B. Effects of a distance learning program on physicians' opioid- and benzodiazepine-prescribing skills. J Contin Educ Health Prof. 2006;26:294-301.
29. Pimlott NJ, Hux JE, Wilson LM, et al. Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. CMAJ. 2003;168:835-839.
30. Roumie CL, Grogan EL, Falbe W, et al. A three-part intervention to change the use of hormone replacement therapy in response to new evidence. Ann Intern Med. 2004;141:118-125.
31. Stewart R, Niessen WJ, Broer J, et al. General practitioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application. J Clin Epidemiol. 2007;60:1076-1084.
32. Tamblyn R, Huang A, Perreault R, et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ. 2003;169:549-556.
33. Zullich SG, Grasela TH Jr, Fiedler-Kelly JB, et al. Impact of triplicate prescription program on psychotropic prescribing patterns in long-term care facilities. Ann Pharmacother. 1992;26:539-546.
34. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23:19-34.
35. Bush TM, Bonomi AE, Nekhlyudov L, et al. How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes. J Gen Intern Med. 2007;22:1311-1316.
36. Palan J, Odutola A, White SP. Is clopidogrel stopped prior to hip fracture surgery-a survey of current practice in the United Kingdom. Injury. 2007;38:1279-1285.
37. Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother. 2008;42:550-557. 10.1345/aph. 1K433.
38. McCann A. Antiplatelet therapy after coronary occlusion. Aust Pre-scriber. 2007;30:92-96.
39. Sekimoto M, Imanaka Y, Kitano N, et al. Why are physicians not persuaded by scientific evidence? A grounded theory interview study. BMC Health Serv Res. 2006;6:92.10.1186/1472-6963-6-92. (Pubitemid 44299821)
40. Bain KT, Holmes HM, Beers MH, et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008;56:1946-1952. 10.1111/j. 1532-5415.2008.01916.x.
41. Dollman WB, LeBlanc VT, Stevens L, et al. Achieving a sustained reduction in benzodiazepine use through implementation of an area-wide multi-strategic approach. J Clin Pharm Ther. 2005;30:425-432.
42. Oxman AD, Thomson MA, Davis DA, et al. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ. 1995;153:1423-1431.
43. Bain KT. Barriers and strategies to influencing physician behavior. Am J Med Qual. 2007;22:5-7. 10.1177/1062860606296147.
44. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151: 1825-1832.
45. Thomsen LA, Winterstein AG, Sondergaard B, et al. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41:1411-1426. DOI: 10.1345/aph.1H658.
46. von Laue NC, Schwappach DL, Koeck CM. The epidemiology of preventable adverse drug events: a review of the literature. Wien Klin Wochenschr. 2003;115:407-415.
47. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA. 1994;272:292-296.
48. Kohn LT, Corrigan JM, Donaldson MS, eds. To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press, 2000.
49. Bates DW, Spell N, Cullen DJ, et al. Adverse Drug Events Prevention Study Group. The costs of adverse drug events in hospitalized patients. JAMA. 1997;277:307-311.
50. Phillips SL, Carr-Lopez SM. Impact of a pharmacist on medication discontinuation in a hospital-based geriatric clinic. Am J Hosp Pharm. 1990;47:1075-1079.
51. Roberts MS, Stokes JA, King MA, et al. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes. Br J Clin Pharmacol. 2001;51:257-265.
52. Laucka PV, Hoffman NB. Decreasing medication use in a nursing-home patient-care unit. Am J Hosp Pharm. 1992;49:96-99.
53. Zarowitz BJ, Stebelsky LA, Muma BK, et al. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy. 2005;25:1636-1645.
54. Plumridge RJ. A review of factors influencing drug prescribing (Part 1). Aust J Hosp Pharm. 1983;13:16-19.
55. Plumridge RJ. A review of factors influencing drug prescribing (Part 2). Aust J Hosp Pharm. 1983;13:44-48.
56. Plumridge RJ. Intervention strategies aimed at modifying prescribing behaviour. Aust J Hosp Pharm. 1984;14:93-100.
57. Raisch DW. A model of methods for influencing prescribing: part I. A review of prescribing models, persuasion theories, and administrative and educational methods. DICP. 1990;24:417-421.
58. Raisch DW. A model of methods for influencing prescribing: part II. A review of educational methods, theories of human inference, and delineation of the model. DICP. 1990;24:537-542.
59. Campo K, De Staebel O, Gijsbrechts E, et al. Physicians' decision process for drug prescription and the impact of pharmaceutical marketing mix instruments. Health Mark Q. 2005;22:73-107. 10.1300/J026v22n04-05.
60. Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25:1021-1031. 10.2165/0002512-20082512000004.